Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies

• Status: Terminated
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase I, open-label, multicenter, dose-escalation trial of VS-4718, a focal adhesion kinase inhibitor, in subjects with metastatic non-hematologic malignancies. This clinical study is comprised of 2 parts: Part 1 (Dose Escalation) and Part 2 (Expansion). The purpose of this study is to evaluate the safety (including the recommended Phase II dose), pharmacokinetics (the amount of VS-4718 in your blood) and the anti-cancer activity of VS-4718. The pharmacodynamic effects (genes or proteins that may predict or show how your body may respond to VS-4718) will also be examined in tumor biopsies and blood samples.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Verastem, Inc.

Criteria

Inclusion Criteria:

• Age ≥ 18 years.

• Histopathologically confirmed diagnosis of a metastatic non-hematologic malignancy.

• ECOG (Eastern Cooperative Oncology Group) performance status of ≤ 2

• Adequate renal function

• Adequate hepatic function (total bilirubin ≤ 1.5x ULN (upper limit of normal) for the institution; AST [aspartate transaminase] and ALT [alanine transaminase] ≤ 3x ULN, or ≤ 5x ULN if due to liver involvement by tumor).

• Adequate bone marrow function (hemoglobin ≥ 9.0 g/dL; unsupported platelets ≥ 100 x10 9 cells/L; absolute neutrophil count ≥ 1.5x10 9 cells/L

• Corrected QT interval (QTc) < 470 ms

• Subjects must have at least one tumor lesion that is suitable for repeat biopsy, and must agree to two tumor biopsies (pre- and post- treatment).

• Willing and able to participate in the trial and comply with all trial requirements.

Exclusion Criteria:

• Gastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication.

• Uncontrolled or severe concurrent medical condition (including uncontrolled brain metastases).

• History of upper gastrointestinal bleeding, ulceration, or perforation within 12 months.

• Known history of stroke or cerebrovascular accident within 6 months.

• Subjects being actively treated for a secondary malignancy.